seasonal allergic rhinitis
Conditions
Interventions
control group:The spleen aminopeptide oral solution simulator was administered from 4 weeks to 6 weeks (±7d) before the pollen sowing period, and the treatment course was 12 weeks in total. Combinati
Sponsors
Beijing Shijitan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: Participants in this study were all patients with a history of seasonal allergies, but were enrolled before pollen spread, that is, before the onset of symptoms. (1) Age 18-69 years old, male or female; (2) Have a typical history of seasonal allergic rhinitis, and the diagnostic criteria for seasonal AR refer to the Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (revised edition 2022); ? Symptoms: Two or more symptoms, such as sneezing, watery nose, nasal itching and nasal congestion, persist or accumulate for more than 1 hour a day, may be accompanied by eye symptoms such as tearing, eye itching and eye redness; ? Signs: common nasal mucosa pale, edema, nasal watery secretions; Allergen testing in the past or at visit: at least one allergen is positive for SPT and/or serum specific IgE; (3) In patients with pollen allergy, the symptoms were more than 4 weeks in the previous pollen dissemination season, and the average TNSS score of patients before treatment was =6. The average score of nasal congestion symptom was =2, and at least one of the three symptom scores of sneezing, runny nose and itchy nose was =2. (4) Voluntary subjects and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Perennial allergic rhinitis, severe nasal septum deviation, sinusitis, nasal polyp patients; (2) patients with serious heart, liver, kidney and brain diseases; (3) pregnant and lactating women; (4) Patients with moderate to severe asthma diagnosed clearly during previous pollen season; (5) Tricyclic antidepressants, immunosuppressors/immunomodulators, and oral hormones were taken 4 weeks before enrollment; (6) Other conditions considered unsuitable for inclusion by the researcher.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| symptom score-VAS visual analog scale;symptom score-RQLQ Scale;TMS;eosinophil count;cytokines; | — |
Primary
| Measure | Time frame |
|---|---|
| symptom score-Four-point method; | — |
Countries
China
Contacts
Public ContactWang Xueyan
Beijing Shijitan Hospital, Capital Medical University
Outcome results
None listed